Prospector
Profile
3-27-001
|
| |
| Rigel Pharmaceuticals, Inc. |
NAICS |
325412 |
| 1180 Veterans Blvd.,
South San Francisco, CA 94080 |
Description |
Pharmaceutical Preparations |
| (650) 624-1100 |
Employees |
159 |
| http://www.rigel.com/ |
Revenue |
(mil) |
12.6000 |
| |
Income |
(mil) |
-74.2700 |
| |
Assets |
(mil) |
115.7900 |
| |
Liability |
(mil) |
33.6100 |
| |
(for the year ended 2007-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Rigel Pharmaceuticals, Inc., posted a net loss of $74.27 million on revenues of $12.60 million for the fiscal year ended December 31, 2007, as compared with a net loss of $37.64 million on revenues of $33.47 million in fiscal year 2006. The Company's balance sheet showed an increase in accumulated deficit from $295.16 million in 2006 to $369.43 million in 2007.
|
| |
|
Intellectual Property:
The Company has over 200 pending patent applications and over 100 issued patents in the United States that are owned or exclusively licensed as well as pending corresponding foreign patent applications. The Company's policy is to file patent applications to protect technology, inventions and improvements to inventions that are commercially important to the development of its business. The Company seeks United States and international patent protection for a variety of technologies, including new screening methodologies and other research tools, target molecules that are associated with disease states identified in screens, and lead compounds that can affect disease pathways. The Company also intends to seek patent protection or rely upon trade secret rights to protect other technologies that may be used to discover and validate targets and that may be used to identify and develop novel drugs. The Company seeks protection, in part, through confidentiality and proprietary information agreements. The Company is also a party to various license agreements to use technologies in research and development. [SEC Filing 10-K 03-07-08]
|
| |
|
Description:
Rigel Pharmaceuticals, Inc., engages in the discovery and development of small-molecule product candidates for the treatment of inflammatory diseases, cancer, and viral diseases in the U. S.
|
| |
|
Officers:
James M. Gower (Chair & CEO); Raul R. Rodriguez (EVP & COO); Donald G. Payan (EVP, Chief Scientific Officer, & Dir.); Robin Cooper (SVP); Elliott B. Grossbard (SVP); Dolly Vance (SVP, Gen. Counsel, & Sec.); Ryan D. Maynard (VP & CFO); Jean Deleage (Dir.); Bradford S. Goodwin (Dir.); Gary A. Lyons (Dir.); Walter H. Moos (Dir.); Hollings C. Renton (Dir.); Peter S. Ringrose (Dir.); Stephen A. Sherwin (Dir.)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock Symbol RIGL; NasdaqGM; 36,471,094 common shares outstanding as of February 29, 2008.
|
| |
| |
| |
| return to main page |
